Research programme: respiratory syncytial virus vaccine - Pevion Biotech
Alternative Names: PEV 4; RSV vaccine - Pevion BiotechLatest Information Update: 04 Nov 2017
At a glance
- Originator Pevion Biotech
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections in Europe (Parenteral, Injection)
- 26 Apr 2010 Pharmacodynamics and immunogenicity data from a Preclinical trial in Respiratory syncytial virus infections released by Pevion Biotech
- 05 Feb 2007 Preclinical development is ongoing